Biomarker neutralizes effect of bevacizumab in pancreas and kidney cancer patients

[News]

Diether Lambrechts (VIB - KU Leuven) said "in two large clinical studies with patients with advanced stages of pancreas and kidney cancer a variant in the DNA was discovered that identified patients who did not respond well to the prescribed course of bevacizumab.

More... (http://www.news-medical.net/news/20120521/Biomarker-neutralizes-effect-of-bevacizumab-in-pancreas-and-kidney-cancer-patients.aspx)